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Chemically-induced diabetic mice and sponta-
neously diabetic NOD mice have been valuable
as recipients for experimental islet transplanta-
tion. However, their maintenance often
requires parenteral insulin. Diabetogenic chem-
icals can be cytotoxic to the host’s immune sys-
tem and to other organs some of which are
often used as the transplant site. Procurement
of diabetic cohorts in the NOD mouse is prob-
lematic due to variability in the age of disease
onset. We show that RIP-Kb mice, which spon-
taneously develop non-immune diabetes due to
over-expression of the H-2Kb heavy chain in
beta cells, offer many advantages as islet trans-
plant recipients. Diabetes is predictable with a
relatively narrow range of onset (4 wk) and
blood glucose levels (23.0+ 4.0 mmol/l for 39
males at 6 weeks of age). The diabetes is mild
enough so that most diabetic mice can be main-
tained to 40 weeks of age without parenteral
insulin. This consistency of diabetes avails that
outcomes of intervention can be interpreted
with confidence.
Keywords: Islet, transplant, streptozotocin,
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INTRODUCTION
Mouse models of pancreatic islet transplan-
tation often use recipients in which insulin-
dependent diabetes has either been chemically
induced with beta-cell cytotoxic agents, strep-
tozotocin or alloxan, or allowed to develop
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cell destruction in the NOD mouse. These
models are valuable, but have some disadvan-
tages. Both chemical agents are hazardous, and
streptozotocin is a carcinogen. The diabeto-
genic effect of these agents is dependent on
multiple factors including mouse strain, sex,
age and nutritional status eg. [1-8]. Their
bioavailability can be variable due to their
instability in solution [1, 9, 10]. As such, it can
be difficult to control precisely the degree of
induced beta-cell damage and consequent dia-
betes. In addition, the toxicity of streptozotocin
and alloxan is not limited to the beta cell.
Streptozotocin has direct effects on the liver
[11], kidney [12] and immune system [13-16].
Likewise, alloxan is nephrotoxic [17] and pos-
sibly hepatotoxic [18]. These effects may com-
promise the interpretation of experimental out-
comes. 
Spontaneously diabetic NOD mice more
closely resemble the clinical situation in
humans and thus it could be argued are more
appropriate recipients than chemically-induced
diabetic mice. However, NOD mice are also
not ideal. They present with diabetes over a
wide time-span of months such that it is diffi-
cult to procure a large cohort of age-matched
diabetic mice for transplant experiments. Once
diabetic, they can only be maintained for 3-4
weeks before requiring insulin injections for
survival. Finally, in studies where allo- or xeno-
responses are being analyzed, it can be difficult
to distinguish them from auto-immune
responses to the graft. 
A number of transgenic insulin-deficient dia-
betic mouse models have also been described
(reviewed [19]), including several which are not
immune-mediated [20-24]. However, none
have been characterized with respect to their
suitability as diabetic hosts for islet transplan-
tation. One of these, the RIP-Kb mouse, trans-
genically overexpresses the H-2Kb class I heavy
chain on the rat insulin promoter (RIP) in pan-
creatic beta-cells [20]. The mechanism of beta-
cell damage by H-2Kb has been proposed to
result from the misfolding of the over-expressed
heavy chain which somehow impairs the nor-
mal secretory pathways [25]. One RIP-Kb line-
age, designated 50-1, develops non-lethal dia-
betes, with mice surviving beyond 20 weeks of
age. We postulated that these mice might obvi-
ate the need for iatrogenic intervention and
develop diabetes with a reliable and predictable
natural history. This should make them auspi-
cious hosts for islet transplantation and inter-
pretation of outcomes.
MATERIALS AND METHODS
MICE
CBA, B6.C-H2bm1 (C57BL/6 with the bm1
mutation of H-2Kb) and C57BL/6-TgN(Rip-
H2-Kb) (lineage 50-1,abbreviated RIP-Kb [25])
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FIGURE 1
Blood glucose levels in female compared with male RIP-Kb mice.
The mean ± SD blood glucose level is shown for n non-diabetic
(hatched bars, transgene negative) or diabetic (filled bars, trans-
gene positive) female or male littermates at 6 weeks of age. mice were bred and maintained at the Walter
and Eliza Hall Institute of Medical Research.
Requests for RIP-Kb mice should be addressed
to Dr Andrew Lew at the Walter and Eliza Hall
Institute. RIP-Kb mice originated in CBA x
B10.BR.F2 mice which were subsequently
backcrossed to B6.C-H2bm1 mice for 35 genera-
tions. Because we generally use CBA mice as
pancreas graft recipients in our laboratory [26,
27], RIP-Kb mice used in the current study were
further backcrossed with CBA mice for at least
5 generations. All experimental procedures
were approved by the Royal Melbourne
Hospital Research Foundation Animal Ethics
Committee.
BLOOD GLUCOSE MEASUREMENTS
Non-fasting blood glucose was determined
between 1-3 pm using Advantage blood glucose
test strips (Roche, Castle Hill, Australia) and
an Advantage Meter (Roche). A drop of blood
was obtained via a glass capillary tube from the
retro-orbital venous plexus of unanesthetised
mice, or by tail bleed of anesthetised mice
undergoing surgery. Mice with confirmed
blood glucose measurements in excess of 11
mmol/l were classified as diabetic. Blood glu-
cose levels are shown either for individual mice
or as the mean + SD for n mice.
STATISTICAL ANALYSIS
Differences between blood glucose levels or
weights were analysed by two-tailed unpaired t
tests using Prism v2.0a (GraphPad Software,
Inc., San Diego, USA).
PANCREATIC ISLET TRANSPLANTS
Islet donors were 6-10 week old male and
female CBA or B6.C-H2bm1 mice. Pancreata
were collagenase-digested, and islets were sepa-
rated by density gradient centrifugation over
Histopaque-1077 (Sigma, St Louis,USA) as
described [28]. Islets were hand-picked and
counted under an inverted microscope.
Between 400-700 islets were injected, via a yel-
low micropipette tip, under the kidney capsule
of 6-10 week old male RIP-Kb recipients. Blood
glucose levels were determined just prior to
islet transplantation then monitored periodical-
ly as indicated. The graft plus kidney were
recovered at the indicated times from mice
which were either killed, or nephrectomized
and allowed to recover before additional blood
glucose determinations. The graft plus kidney
were fixed in Bouin’s solution before sectioning
and staining with hematoxylin and eosin. 
RESULTS
DIABETES IS MORE SEVERE IN MALE RIP-Kb MICE
Diabetes incidence was compared in male
and female mice (Figure 1). As expected, non-
transgenic offspring do not develop diabetes.
At six weeks of age diabetic male mice had a
blood glucose of 23.0+ 4.0 mmol/l compared to
16.8 + 2.2 mmol/l in diabetic females (p <
0.0001). This rather tight standard deviation
allows for reliable determination of any suc-
cessful intervention. There was no overlap
between diabetic and non-diabetic mice (Figure
2). Indeed, the difference in mean blood glu-
cose between non-diabetic and diabetic mice at
6 weeks of age was 9.9 and 14.5 mmol/l for
females and males respectively (Figure 1). This
margin of difference should allow the use of
mice of either sex as transplant recipients,
although this margin is greater for male mice.
Male recipients are also desirable in that donor
pancreas of any sex can be transplanted with-
out concern for H-Y antigen differences. This is
particularly important for fetal tissue trans-
plantation, as the sex may be unknown.
DIABETES IN MALE RIP-Kb MICE DEVELOPS
EARLY, IS STABLE AND DOES NOT REQUIRE INSULIN
INJECTIONS
A more comprehensive analysis of blood glu-
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second cohort of male mice (Figure 2). Diabetes
of moderate severity (16.8 + 3.1 mmol/l) devel-
oped by 4 weeks of age in 96% of transgenic
mice. The severity of diabetes increased by 6
weeks of age (22.2 + 4.4 mmol/l) and blood
glucose levels remained in excess of 20 mmol/l
from 6 – 40 weeks. Five mice were followed out
to 40 weeks of age. They continued to rear
well, but were clearly smaller than non-diabet-
ic littermates. One of these mice had a blood
glucose above the limit of detection (33.3
mmol/l), was slightly hunched and had ruffled
fur. All mice were killed at 40 weeks of age.
RIP-Kb mice have delayed weight gain. The
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FIGURE 2
Blood glucose levels in male RIP-Kb mice. Blood glucose levels
are shown for individual diabetic (closed symbols, transgene
positive ) and non-diabetic (open symbols, transgene negative)
littermates. One mouse at 40 weeks of age had a blood glucose
in excess of the 33.3 mmol/l limit of detection.
FIGURE 3
Hematoxylin and eosin stains (x200) of (A) the pancreas of a 13
week RIP-Kb male, (B) a syngeneic CBA islet graft under the kid-
ney capsule of a RIP-Kb mouse, 98 days post-transplant, and (C)
an allogeneic islet graft under the kidney capsule of a RIP-Kb
mouse, 17 days post-transplant, showing islet destruction and
residual mononuclear cell infiltrate.development of diabetic compared to non-dia-
betic mice was assessed by weighing mice at 5,
15 and 27 weeks of age (Table 1). The weight
of diabetic mice increased from 16.8 + 1.3 g at
5 weeks to 23.0 + 0.7 g at 15 weeks (p <
0.0001), and at these times was only 10-12%
less than non-diabetic littermates (p < 0.05).
Diabetic mice failed to gain weight between 15
and 27 weeks, and rather had some weight lost.
The 27 week weight of 20.1 + 1.7 g was 13%
less than that of the same mice at 15 weeks
(p<0.01), and 31% less than that of non-dia-
betic littermates (p<0.001). At 27 weeks, 4/5
diabetic mice appeared healthy; one was
hunched, had ruffled fur and was killed.
RIP-Kb MICE EXHIBIT NO EVIDENCE OF ISLET
AUTOIMMUNITY BUT REJECT ALLOGENEIC
PANCREATIC ISLET GRAFTS
We next examined the suitability of RIP-Kb
mice for use as islet transplant recipients. The
development of diabetes in RIP-Kb mice is not
immune-dependent: diabetes develops even if
mice are neonatally-thymectomized [20] or are
on an athymic nude mouse background [29]. In
euthymic mice, diabetes develops in the absence
of islet infiltration ([20], Figure 3A; a mouse
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FIGURE 4
Blood glucose levels in RIP-Kb recipients of (A) syngeneic CBA
or (B) allogeneic B6.C-H2bm1 islet grafts. Removal of the graft-
bearing kidney by nephrectomy in 3/5 recipients of syngeneic
and 1/11 recipients of allogeneic islet grafts is indicated by an
arrow.
TABLE 1  RIP-Kb mice have delayed weight gain.
Mouse age Diabetic n Blood glucose Weight
(weeks) (mmol/l)* (g)*
5 - 7 9.5 ± 1.3 18.7 ± 1.7
+ 7 19.8 ± 4.1 16.8 ± 1.3
15 - 5 7.8 ± 0.6 26.1 ± 2.6
+ 5 24.0 ± 3.7 23.0 ± 0.7
27 - 5 6.2 ± 0.5 29.1 ± 3.1
+ 5 22.5 ± 5.6 20.1 ± 1.7
*Mean ± SD for male micewith blood glucose 25.3 mmol/l). The absence
of an islet specific autoimmune response in the
RIP-Kb mice was further supported by the abil-
ity of syngeneic CBA islet transplants to reverse
diabetes and maintain normoglycemia for the
98 day duration of the experiment (Figure 4A).
Normoglycemia could be established by trans-
planting 400 islets. Transplants of fewer islets
have not been attempted. Normoglycemia was
reversed by nephrectomy of the graft-contain-
ing kidney (Figure 4A), indicating that the
function of endogenous RIP-Kb expressing
islets remained impaired in the absence of
hyperglycemic stress. The recovered syngeneic
grafts contained numerous islets, but no
immune infiltrate (Figure 3B).
Allogeneic islet transplants initially reversed
diabetes in RIP-Kb mice. In 9/11 mice the trans-
plants were rapidly infiltrated by mononuclear
cells and rejected (Figure 3C), such that blood
glucose levels returned to pre-transplant levels
by 21 days post-transplant (Figure 4B). In 2/11
mice, the response was less vigorous. These
mice had numerous intact islets surrounded by
peri-islet mononuclear infiltrates when grafts
were recovered 24 and 104 days post-trans-
plant. Mild diabetes (around 14 mmol/l) at the
time of graft recovery was suggestive of
impaired islet function (Figure 4B). Graft
recovery at 104 days post-transplant by
nephrectomy resulted, as for syngeneic grafts,
in a return of the blood glucose to the pre-
transplant level (20.1 mmol/l).
DISCUSSION
RIP-Kb mice develop a spontaneous, non-
immune diabetes as a consequence of overex-
pression of the H-2Kb heavy chain under the
control of RIP [20]. It has been proposed that
the H-2Kb heavy chain is misfolded in the
absence of β2M light chain, and accumulates in
insulin secretory granules thereby disrupting
the processing and secretion of insulin [25].
Indeed, β2M expressed under the control of RIP
can be detected in the insulin secretory gran-
ules, and its coexpression with the H-2Kb heavy
chain reduces the severity of RIP-Kb diabetes
[25]. Transgenic expression of various other
molecules including class II MHC molecules
[21, 22], calmodulin [24], and H-ras [23],
under the control of the insulin promoter can
also result in non-immune mediated diabetes.
However, it remains moot whether any of these
mice will be suitable as diabetic hosts for islet
transplantation. Some are clearly not. For
example, the RIP-ras mice develop diabetes late
(5 months), become severely diabetic and die
within a few weeks [23]. The RIP-calmodulin
mice develop diabetes within hours of birth and
at least some lines suffer from fertility problems
[24]. The current study has shown that the RIP-
Kb class I heavy chain transgenic mouse has
several characteristics that are desirable in
recipients of allo- and xeno-geneic islet trans-
plants. Diabetes develops early and in a pre-
dictable and uniform fashion such that by 6
weeks of age male mice routinely have a blood
glucose level of between 20-28 mmol/l.
Consequently, groups of mice matched for age,
sex and degree of diabetes can be acquired with
ease. In practical terms, mice can be screened at
4 weeks of age: there are no false positives,
while false negatives (due to incomplete expres-
sion of the diabetic phenotype at this early
time-point) are rare and unimportant as they
are discarded. By contrast, diabetes onset in
NOD mice is relatively late and in our colony
varies from 14 - 28 weeks of age, which does
not facilitate acquisition of diabetic cohorts.
The production of diabetic groups can also be
problematic with streptozotocin or alloxan,
because even when mouse strain, age and sex
are matched, the diabetogenic effect is variable.
This can be addressed in part by determining
the appropriate dose for a given mouse strain
and weighing individual mice prior to injection.
42 SUTHERLAND, ET AL.
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCHHowever, other factors such as drug instability
are not so easily controlled. Both streptozo-
tocin and alloxan have short half-lives in aque-
ous solution and plasma (reviewed [1]). The
effective dose of streptozotocin is dependent on
the ratio of alpha and beta anomers [9], which
varies between manufacturers, batches and
time in solution [10, 30]. Clearly, diabetes
induced by streptozotocin or alloxan entails
more variables, is less predictable and is more
labour intensive than in the RIP-Kb model.
Streptozotocin and alloxan are also toxic and,
in the case of streptozotocin, carcinogenic,
necessitating appropriate safety measures to
protect researchers and animal technicians.
The general toxicity of diabetogenic drugs
may influence graft survival and confound
interpretation of results. Islets are usually graft-
ed under the kidney capsule of mice, and less
often into the liver, spleen or testes. Notably,
the liver is a clinically relevant graft site in
humans [31]. Streptozotocin can alter liver
morphology and impairs liver function [11].
Nephrotoxic effects have also been described
[12]. Alloxan causes atrophy of kidney tubules
and interstitial nephritis [17], and is a potential
liver toxin [18]. While it is unknown how such
effects impact on graft outcome, an advantage
of RIP-Kb mice is that pathologies at the graft
site are limited to the secondary effects of dia-
betes and the graft procedure itself.
Streptozotocin is also directly toxic to thy-
mocytes and bone marrow cells [13-15], and
mutagenic for splenocytes due to its capacity to
induce DNA strand breaks [16]. The function-
al consequences of streptozotocin treatment
include suppression of cell-mediated immune
responses independent of hyperglycemia [13,
14, 16]. Thus, with streptozotocin it may be
difficult to attribute outcomes to an experi-
mental immunosuppressive regimen. Similarly,
the abnormal immune system of NOD mice
may influence the nature of graft rejection. Pre-
activated autoimmune effectors present in dia-
betic NOD mice may dominate the emerging
allo- or xeno-response and thus confound
analysis. No such immune perturbations occur
in the RIP-Kb mouse. Delayed rejection of allo-
geneic B6.C-H2bm1 islets occurred in 2/11 RIP-
Kb mice, but was not considered indicative of
an immunocompromised state. In these two
cases the host RIP-Kb mice had been back-
crossed to CBA mice for 5 - 6 generations, and
we consider it likely that they retained some
parental B6.C-H2bm1 histocompatibility genes.
More recent B6.C-H2bm1 transplants into RIP-
Kb mice, backcrossed for 9 - 10 generations,
have been uniformly rejected by day 21 post
transplant.
Spontaneous reversal of diabetes due to beta-
cell neoplasia or neogenesis can occur, when
using streptozotocin or alloxan induced diabet-
ic hosts [3, 32-35]. Thus, it can be difficult to
determine whether reversal of diabetes is due to
this or to the grafting procedure. Hence, it is
desirable to confirm graft function at the con-
clusion of an experiment, for instance by
nephrectomy of a graft bearing kidney and
reversion to hyperglycemia. Such confirmation
is not feasible when grafting into sites such as
the liver since the graft cannot be removed
without the death of the host. Our experience
in RIP-Kb mice shows that diabetes is stable
with increasing blood glucose with age and the
loss of host beta-cell function is not reversible
even when hyperglycemic stress is relieved by
syngeneic islet grafts. Logically, even if neogen-
esis of host beta cells does occur, the function of
the neo-beta cells should be impaired by
expression of the RIP-Kb transgene.
Furthermore, the RIP-Kb mouse has no
predilection to beta-cell neoplasia unlike mod-
els using mutagenic reagents such as streptozo-
tocin. Thus, we propose that reversal of hyper-
glycemia in RIP-Kb mice can be more reliably
attributed to the graft than in alloxan or strep-
tozotocin treated diabetic mice.
The long-term survival of diabetic mice with-
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advantage when grafting stem cell or fetal tis-
sue grafts that do not result in immediate rever-
sal of diabetes. NOD mice require insulin treat-
ment within 3-4 weeks of onset of diabetes in
order to survive, while chemically-induced dia-
betic mice may require immediate insulin treat-
ment. All RIP-Kb mice can reliably be main-
tained without parenteral insulin for >20 weeks
after the onset of diabetes; the vast majority
even longer. Despite blood glucose levels in
excess of 20 mmol/l from 6 weeks of age, they
generally remain healthy although they do not
grow as rapidly as wild type mice. By 27 weeks
the occasional mouse shows signs of discomfort
(hunching, ruffling of fur, reduced activity) and
must be killed, but it is possible to maintain
most mice out to 40 weeks of age. If mice are
transplanted at 6 weeks of age, this provides a
period of up to 34 weeks during which grafts
can mature in vivo. If glucose toxicity for graft-
ed tissue is a consideration, the stable hyper-
glycemia in the RIP-Kb mouse, should be more
readily normalized than hyperglycemia in
NOD or chemically-induced diabetic mice.
Furthermore, the stability of RIP-Kb diabetes
means that in the absence of parenteral insulin,
even partial reductions in blood glucose, eg.
from >20 to about 14 mmol/l in the case of
allografts with peri-islet infiltration in the cur-
rent study, can be interpreted with confidence
as evidence of graft function.
It is clear that as pancreatic islet transplant
recipients RIP-Kb mice offer advantages with
respect to ease of use, stability of diabetes, lack
of autoimmune effects, and lack of iatrogenic
effects (from injecting cytotoxic agents, or
insulin). The introduction of the RIP-Kb model is
particularly timely in view of current intense
interest in the transplant of stem cells and fetal
pig tissue, and transplants into the liver. It will be
of additional interest to determine if RIP-Kb mice
are a useful model for studying chronic hyper-
glycemia and potential diabetic complications.
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